

July 19, 2024

<p>To</p> <p>The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai – 400 001</p> <p>Code: 540222</p>	<p>To</p> <p>The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051</p> <p>Code: LAURUSLABS</p>
--	---

Dear Sir / Madam,

Sub: Q1 FY 25 Earnings conference call invite

Please find enclosed the Q1 FY 25 Earnings conference call invite for the call scheduled on July 25, 2024 at 05.00 PM (IST).

This is for your information and records.

Thanking you,

Yours sincerely,

For Laurus Labs Limited

G. Venkateswar Reddy
Company Secretary &
Compliance Officer

Encl: As above

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Laurus Labs Q1 FY25 Results Conference Call

25 July 2024 at 5:00pm IST

Hyderabad, July 19, 2024: Laurus Labs Ltd (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company will organize a conference call to discuss Q1 FY25 results followed by an interactive Q&A. The call will be hosted by Antique Stock Broking. Dial In and other details given below

Date and Time	Thursday, July 25, 2024 - 5:00 pm IST
Conference Dial-in	
Primary Number	+91 22 6280 1342
Secondary Number	+91 22 7115 8243 <i>Available all over India</i>
Singapore	800101 2045
Hong Kong	800964 448
Japan	00531161110
USA	1 866 746 2133
UK	0 808 101 1573
Diamond Pass	Event Link

END

Investors Relations Vivek Kumar T +91 40 3980 4366 investorrelations@lauruslabs.com	Media Relations Karthik C T +91 40 3980 4380 mediarelations@lauruslabs.com
--	--

Corporate Office

2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India
T +91 40 6659 4333, 3980 4333, 2342 0500/501 F +91 40 6659 4320 / 3980 4320

Registered Office

Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anapalli District - 531021, Andhra Pradesh, India
CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com



About Laurus Labs

As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. Since our inception in 2005, we have been developing and manufacturing APIs and Intermediates. We have global leadership position in APIs, including anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics. Our position was strengthened by our backward-integration and strong regulatory compliance across all operations. We emerged as one of the most trusted CMO and Contract Development and Manufacturing Organization (CDMO) service provider to Global Innovators from drug development phase to commercial manufacturing. Laurus employs 6700+ people, including around 1,100+ scientists across 14 manufacturing sites approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2024 Laurus generated ₹ 5,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated "BBB" by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Follow @ Laurus Labs on [LinkedIn](#) | [Twitter](#) | [Facebook](#) | [Instagram](#)